Spots Global Cancer Trial Database for pharmacokinetic study

Every month we try and update this database with for pharmacokinetic study cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma	NCT03013933	Recurrent Hodgk... Refractory Hodg...	Brentuximab Ved... Cyclosporine Pharmacokinetic... Verapamil Verapamil Hydro...	15 Years -	City of Hope Medical Center
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	NCT03479268	B-Cell Prolymph... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... Richter Syndrom...	Ibrutinib Laboratory Biom... Pevonedistat Pharmacokinetic... Pharmacological...	18 Years -	City of Hope Medical Center
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy	NCT01643408	Acute Lymphobla... Lymphoblastic L...	asparaginase Er...	1 Year - 30 Years	Jazz Pharmaceuticals
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant	NCT03259503	Recurrent Diffu... Recurrent T-Cel... Refractory Diff... Refractory Hodg... Refractory T-Ce...	Busulfan Gemcitabine Melphalan Olaparib Peripheral Bloo... Pharmacokinetic... Rituximab Vorinostat	18 Years - 65 Years	M.D. Anderson Cancer Center
Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005	NCT00544258	Actinic Keratos...	PEP005	18 Years -	Peplin
Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer	NCT00128531	Prostate Cancer	leuprolide acet...	18 Years -	GP-Pharm
Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)	NCT02953743	Unresectable He...	Lenvatinib	18 Years -	Eisai Inc.
FID-007 in Treating Participants With Advanced Solid Tumors	NCT03537690	Advanced Malign... Refractory Mali...	Laboratory Biom... PEOX-based Poly... Pharmacokinetic...	18 Years -	University of Southern California
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	NCT03479268	B-Cell Prolymph... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... Richter Syndrom...	Ibrutinib Laboratory Biom... Pevonedistat Pharmacokinetic... Pharmacological...	18 Years -	City of Hope Medical Center
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	NCT03698994	Advanced Malign... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Histi... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Refractory Epen... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Hist... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Prim... Refractory Rhab... Refractory Rhab... Refractory Soft... Wilms Tumor	Pharmacokinetic... Ulixertinib	12 Months - 21 Years	National Cancer Institute (NCI)
JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia	NCT03557970	Recurrent Acute... Refractory Acut...	Edicotinib Pharmacokinetic...	18 Years -	OHSU Knight Cancer Institute
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment	NCT05627245	Recurrent B-Cel... Recurrent Diffu... Recurrent Non-H... Recurrent Prima... Recurrent T-Cel... Recurrent Trans... Refractory B-Ce... Refractory Diff... Refractory Non-... Refractory Prim... Refractory T-Ce... Refractory Tran...	Belinostat Biopsy Biospecimen Col... Computed Tomogr... Pharmacokinetic... Positron Emissi... Tazemetostat	18 Years -	National Cancer Institute (NCI)
TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors	NCT03756818	Advanced Malign... Ovarian Carcino... Refractory Mali... Refractory Ovar...	Mivavotinib Paclitaxel Pharmacokinetic...	18 Years -	M.D. Anderson Cancer Center
BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma	NCT03502577	Recurrent Plasm... Refractory Plas...	BCMA-specific C... Cyclophosphamid... Fludarabine Gamma-Secretase... Laboratory Biom... Pharmacokinetic...	21 Years -	Fred Hutchinson Cancer Center
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer	NCT03552471	BRCA1 Gene Muta... BRCA2 Gene Muta... Folate Receptor... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Uteri... Recurrent Uteri... Platinum Resist...	Laboratory Biom... Mirvetuximab So... Pharmacokinetic... Rucaparib Camsy...	18 Years -	Ohio State University Comprehensive Cancer Center
sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer	NCT03552796	Recurrent Bladd... Bladder Cancer ... Bladder Cancer ...	Pharmacokinetic... Recombinant Eph...	18 Years - 80 Years	University of Southern California
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	NCT03698994	Advanced Malign... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Histi... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Refractory Epen... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Hist... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Prim... Refractory Rhab... Refractory Rhab... Refractory Soft... Wilms Tumor	Pharmacokinetic... Ulixertinib	12 Months - 21 Years	National Cancer Institute (NCI)
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis	NCT03508570	Malignant Perit... Malignant Retro... Metastatic Cerv... Metastatic Endo... Metastatic Fall... Metastatic Mali... Metastatic Ovar... Metastatic Prim... Peritoneal Carc... Platinum-Refrac... Platinum-Refrac... Platinum-Refrac... Platinum-Refrac... Platinum-Resist... Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Cervi... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVB Cervi... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri...	Ipilimumab Laboratory Biom... Nivolumab Pharmacokinetic...	18 Years -	M.D. Anderson Cancer Center
sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer	NCT03552796	Recurrent Bladd... Bladder Cancer ... Bladder Cancer ...	Pharmacokinetic... Recombinant Eph...	18 Years - 80 Years	University of Southern California
Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia	NCT01093573	Untreated Adult...	midostaurin azacitidine bone marrow asp... mutation analys... Pharmacokinetic...	-	Case Comprehensive Cancer Center
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia	NCT03506373	Recurrent Walde... Refractory Wald... Waldenstrom Mac...	Ibrutinib Ixazomib Citrat... Laboratory Biom... Pharmacodynamic... Pharmacokinetic...	18 Years -	Mayo Clinic
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis	NCT03508570	Malignant Perit... Malignant Retro... Metastatic Cerv... Metastatic Endo... Metastatic Fall... Metastatic Mali... Metastatic Ovar... Metastatic Prim... Peritoneal Carc... Platinum-Refrac... Platinum-Refrac... Platinum-Refrac... Platinum-Refrac... Platinum-Resist... Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Cervi... Recurrent Endom... Recurrent Fallo... Recurrent Malig... Recurrent Ovari... Recurrent Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVB Cervi... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima... Stage IVB Uteri...	Ipilimumab Laboratory Biom... Nivolumab Pharmacokinetic...	18 Years -	M.D. Anderson Cancer Center
Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005	NCT00544258	Actinic Keratos...	PEP005	18 Years -	Peplin
FID-007 in Treating Participants With Advanced Solid Tumors	NCT03537690	Advanced Malign... Refractory Mali...	Laboratory Biom... PEOX-based Poly... Pharmacokinetic...	18 Years -	University of Southern California
Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia	NCT01093573	Untreated Adult...	midostaurin azacitidine bone marrow asp... mutation analys... Pharmacokinetic...	-	Case Comprehensive Cancer Center
Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer	NCT03520842	KRAS Gene Mutat... Metastatic Mali... Recurrent Non-S... Stage IV Non-Sm...	Methotrexate Pharmacokinetic... Regorafenib	18 Years -	Stanford University
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer	NCT03552471	BRCA1 Gene Muta... BRCA2 Gene Muta... Folate Receptor... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Uteri... Recurrent Uteri... Platinum Resist...	Laboratory Biom... Mirvetuximab So... Pharmacokinetic... Rucaparib Camsy...	18 Years -	Ohio State University Comprehensive Cancer Center
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant	NCT03259503	Recurrent Diffu... Recurrent T-Cel... Refractory Diff... Refractory Hodg... Refractory T-Ce...	Busulfan Gemcitabine Melphalan Olaparib Peripheral Bloo... Pharmacokinetic... Rituximab Vorinostat	18 Years - 65 Years	M.D. Anderson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: